OXB.L - Oxford BioMedica PLC

LSE - LSE Delayed price. Currency in GBp
8.60
-0.22 (-2.49%)
At close: 4:30PM BST
Stock chart is not supported by your current browser
Previous close8.82
Open8.86
Bid8.60 x 2513500
Ask8.70 x 11600000
Day's range8.60 - 8.93
52-week range3.11 - 11.50
Volume2,087,908
Avg. volume7,563,652
Market cap266.79M
Beta-1.52
PE ratio (TTM)-21.50
EPS (TTM)N/A
Earnings dateN/A
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Reuters - UK Focus2 months ago

    BUZZ-Oxford BioMedica: shares jump 12 pct as U.S. approves gene therapy

    ** Oxford BioMedica shares up 12% as Novartis wins approval for pioneering leukaemia treatment, marking the first gene therapy approval in the United States ** UK company makes virus-based gene delivery ...

  • Reuters - UK Focus2 months ago

    Profit finally in sight for gene therapy specialist Oxford Bio

    After 20 years of losses, gene therapy specialist Oxford BioMedica (LSE: OXB.L - news) is at last close to achieving its first profit thanks to the success of Novartis with a pioneering cancer treatment. As manufacturer of the virus-based gene delivery system central to the Novartis therapy, which re-engineers a patient's immune cells to attack cancer, the small British company will receive a modest slice of the revenue once the new drug is approved.

  • Reuters - UK Focus3 months ago

    Oxford BioMedica wins big contract for Novartis cell therapy

    Novartis (IOB: 0QLR.IL - news) has signed a major contract with Oxford BioMedica (LSE: OXB.L - news) that could earn the British company more than $100 million over three years for supplying the Swiss drugmaker with material for its novel cell therapy CTL019. The deal, announced by Oxford BioMedica on Thursday, could help put the veteran biotech firm on a path to sustainable profitability. The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukaemia that is expected to reach the market this year.

  • Reuters - UK Focus7 months ago

    Novartis wins speedy U.S. review of new leukaemia drug

    A new leukaemia treatment from Novartis (IOB: 0QLR.IL - news) for children and young adults will get priority review from the U.S. Food and Drug Administration (FDA), putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. The FDA's announcement late Wednesday means the regulator plans to take action within six months on Novartis's so-called chimeric antigen receptor T cell therapy, or CAR (HKSE: 0699-OL.HK - news) -T, in partnership with University of Pennsylvania researchers.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes